Ipca Laboratories delivered exceptional Q1FY27 results that exceeded analyst expectations across all parameters. According to reports from Business Standard, the pharmaceutical company achieved 21% revenue growth driven primarily by exports, which posted a 34% jump for the fourth consecutive quarter. The strong performance was supported by a 107% surge in institutional generics and 27% rise in generics business, while branded rest-of-the-world markets grew 16%. Domestic market revenue grew 13% year-on-year, comprising 5% volume growth, 4.5-5% pricing uptick, and 2% contribution from launches.
The company demonstrated significant operational improvements with consolidated gross margin expanding 135 basis points year-on-year to 71% and operating profit margin reaching 22.9%, up 450 basis points from the previous year. As reported by Business Standard, Ipca successfully passed on raw material cost increases to API customers and implemented price hikes in both Indian and international branded generics segments. The company upgraded its FY27 revenue growth guidance to 14-16% from 12-13% and raised consolidated operating profit margin guidance to 23% from 22%.
Multiple brokerages raised their revenue and earnings estimates for FY27 and FY28 following the strong quarterly performance. According to Business Standard, Nomura Research raised earnings estimates by 13% and maintained a 'buy' rating with a September 2027 target price of ₹2,060, while Motilal Oswal Research also maintained a 'buy' rating with a target price of ₹2,060. At the current price of ₹1,932, the stock is trading at 27x FY28 estimated earnings, leaving only marginal upside based on earnings projections and target prices.
The domestic formulation segment continued its strong performance with 17% growth in chronic therapies and 9% growth in acute segment, led by cardiovascular, antidiabetic therapies, dermatology, and ophthalmology segments. As reported by Business Standard, after two quarters of weak performance, the API segment witnessed a strong revival in growth during the quarter. The domestic formulation and branded generics business now contributes 46% of revenues and 70% of operating profit, positioning it as a key growth driver going forward.
